Viewing nowCombinationJanugreen Duo tablet 50/850 milligrams
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.

MFDS item code 202200910 · Approved 2022.03.02 · Insurance code 650304370
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood glucose in patients with type 2 diabetes. It can be used especially in cases where patients have never received diabetes medication before or when sufficient blood glucose control cannot be achieved with monotherapy. Additionally, it is effective when blood glucose is not adequately controlled with either metformin or sitagliptin alone, or when substituting a combined therapy of the two drugs. Furthermore, it can be administered in combination with metformin and sulfonylurea, or metformin and thiazolidinedione when blood glucose control is not achievable with those regimens. It also aids in blood glucose control when insulin and metformin combination therapy is insufficient. Therefore, this medication is used in various therapeutic situations to improve blood glucose control in patients with type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be based on the patient’s current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, “Patients who must not receive this medicine,” under Precautions for Use). 2. Patients treated with metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may begin with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, “General precautions,” under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, “Patients who must not receive this medicine,” under Precautions for Use).
This medication contains both sitagliptin and metformin and is primarily used for the treatment of type 2 diabetes. Serious allergic reactions may occur while taking this medication, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear, discontinue use immediately and consult a physician. There is a risk of developing acute pancreatitis, so it is essential to notify healthcare professionals if severe abdominal pain, vomiting, or nausea occurs. This medication should not be administered to patients with poor kidney function, and dosing should be discontinued or adjusted based on kidney function test results. It should not be used in situations that could affect kidney function, such as heart failure, acute myocardial infarction, severe infections, dehydration, or acute illnesses. Women who are pregnant or may become pregnant, or those who are breastfeeding, should not take this medication. This medication may cause hypoglycemia, so caution is needed for those skipping meals, having irregular eating habits, or engaging in excessive exercise; the risk of hypoglycemic symptoms may be heightened when combined with other hypoglycemic agents. Regular kidney function and blood tests should be conducted during treatment, and supplementation may be necessary if vitamin B12 levels decrease. Alcohol consumption may increase the risk of side effects with this medication, so it is advisable to avoid drinking. Before surgery, consult with a physician and discontinue this medication 48 hours prior, and resume only after confirming normal kidney function post-surgery. Severe joint pain or skin disorders may occur rarely during treatment; notify healthcare professionals immediately if these symptoms occur. In cases of overdose, seek immediate medical attention, as the medication can be removed through hemodialysis. This medication can be used in the elderly, but dose adjustments and regular monitoring are necessary due to common age-related declines in kidney function. Maintain regular meals and exercise, and consistently monitor blood glucose and kidney function, consulting with a physician immediately if any unusual symptoms arise.
Anaphylaxis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air, at room temperature between 1 and 30 degrees Celsius. Proper storage can help maintain the efficacy of the medication for a longer period.
Pink oval film-coated tablet
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.